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mentioned in the study, but they were kept in the department for
further observation and evaluation. Unfortunately, the objective
parameters before discharge such as Post-Anesthetic Discharge
Scoring System or Aldrete scoring systemwere not used. The long
term follow up and side effects related to sedation were not done
in our study.
Regarding the hypoxemia events, all the subjects received
supplementary oxygen by nasal prongs. The hypoxemia events,
which were slight and transient, were noticed only in the cir-
rhotic group. The statement that this group might be more prone
to develop desaturation could be true, albeit, with no statistical
signiﬁcance. The American Society of Anesthesiologists Physical
Status (ASA) score was not calculated, although, this parameter
may inﬂuence the recovery time [2].
In conclusion, we agree that it is better and safer to apply a
multiple psychometric tests before discharging, but this can off-
set the advantage of the reduced recovery time in patients
sedated with propofol. Longer follow up period can easily be
taken even by a phone call 1–2 days after the procedure. Accord-
ing to this approach, MHE can be diagnosed and treated rapidly.
Finally, a discharge from the hospital at 2 h post endoscopy
seems to be very safe [3].
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JOURNAL OF HEPATOLOGYAcute autochthonous hepatitis E in western patients with
underlying chronic liver disease: A role for ribavirin?To the Editor:
We read with interest the recent editorial in the Journal of Hepa-
tology entitled ‘‘Hepatitis E: Water, water everywhere – Now a
Global Disease’’ [1]. The authors state that in industrialized
nations, acute liver failure and acute-on-chronic liver failure
due to autochthonous acute hepatitis E genotype 3 (HEV3) infec-
tion have not yet been documented. This statement is inaccurate.
A series of seven patients with fulminant liver failure from acute
autochthonous HEV3 infection have been reported from south-
west France [2]. Six of these patients had chronic liver disease
and ﬁve were active drinkers. Five of these patients died. In
addition, acute HEV3 infection was reported as a cause of decom-
pensation in three patients with chronic liver disease in the UK
[3]. Two of these patients died from sub-acute liver failure.
In the past three years (January 2008–December 2010) 35
more cases of acute hepatitis E in immunocompetent patients
were diagnosed in the Toulouse University Hospital. Of these,
nine patients (26%) had underlying chronic liver disease, of which
seven were alcoholic. There were seven males and the median
age was 47 years (36–79). All cases were autochthonous. Four
patients (44%) had ascites and two had encephalopathy. Median
serum bilirubin was 127 lmol/L (29.6–704.4). The strains were
sequenced in four patients. They were all genotype 3; subtype
3f in three patients, subtype 3c in one. Three patients died (33%).
The two most recent patients were treated with ribavirin
monotherapy. A 79 year old patient with chronic liver disease
was admitted for acute hepatitis and acute kidney failure requir-
ing renal replacement therapy. HEV RNA was found to be positive
both in the serum and the stools and all other causes of hepatitis
were ruled out, including acute alcoholic hepatitis. Because of the
severe presentation, the advanced age of the patient, and since
we had shown earlier this year that ribavirin is effective and wellJournal of Hepatology 201tolerated in the treatment of chronic hepatitis E in kidney-trans-
plant patients [4], he was given ribavirin monotherapy in order to
rapidly contain viral replication. Ribavirin was started off at a
dose of 200 mg every other day because of the acute kidney fail-
ure. The treatment was scheduled for a 3 month period. Serum
HEV RNA concentration decreased from 6.36 log copies/ml at the
initiation of the therapy to 4.6 log copies/ml at day 10, 2.9 log
copies/ml at day 17, and was negative at one month. The patient
completely recovered and dialysis was stopped at month two.
The second patient was treated for 10 days at a dose of
1000 mg per day in two divided doses. Viral load was 4.07 log-
copies/ml before treatment, 3.08 after 3 days, 2.54 after 6 days
and undetectable one month later. Hemoglobin levels dropped
from 12.6 g/dl before treatment to 11.6 g/dl after 6 days of treat-
ment. There were no other ribavirin induced side effects. There
was no viral relapse in these two patients.
These data show that the prognosis of acute autochthonous
hepatitis E can be poor in industrialized nations, particularly in
patients with chronic liver disease (acute on chronic liver failure),
and is similar to that reported for HEV genotype 1 infection in
patients with chronic liver disease in the Indian sub-continent
[5]. An Anglo-Frenchmulticentre study is ongoing to assess its fre-
quency and its induced-mortality in a larger number of patients.
Short term ribavirin treatment may be useful in these patients.
However, this hypothesis needs to be further investigated.
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This is a reply to the Letter to the Editor by Peron et al.
We deeply appreciate the information provided by Peron et al.
[1] about two short reports emanating from France [2] and UK [3]
indicating that Genotype 3 HEV have been implicated in the
cause of Acute on Chronic Liver Failure (ACLF) in 9 out of 10
patients, most of whom (n = 7) had underlying alcoholic cirrhosis.
Indeed, it conﬁrmed our suggestion that, such events might be
occurring in industrialized nations and HEV may be associated
with causing ACLF even in non-endemic developed nation [4].
In these geographical areas, autochthonous Genotype 3 HEV
infections in human are implicated as a zoonotic disease and pigs
have been identiﬁed as the reservoir of Genotype 3 HEV. Interest-
ingly, a national survey of acute hepatitis E in France, which
included 19 centres reported that 47 among 53 autochthonous
HEV (majority Genotype 3) infection documented during the
study period might have been due to contaminated water in
many of them [5]. Further, Peron et al in their letter to editor
[1] stated that 26% (9 out of 35) of acute hepatitis E documented
at their centre had underlying chronic liver disease, most of
whom were alcoholic (7 out of 9) [unpublished observation]. This
observation may indicate that, patients with underlying chronic
liver disease may be more prone to contract acute HEV infection
which we have documented and reported [6]. As mentioned ear-
lier, the source of HEV infection may be from water and not nec-
essarily due to only zoonotic transmission, as documented in
France [5]. Therefore, Genotype 3 may also be transmitted
through contaminated water and may cause severe liver disease,
particularly in those with underlying alcoholic liver disease; it
thus needs to be conﬁrmed by prospective evaluation whether
contaminated water is the source of such infection causing ACLF.
However, after diagnostic assays for HEV became available,
prospective studies including large number of patients with acute
liver failure (ALF) from developed nation [7,8] did not report HEV
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as an etiological agent. Furthermore, reviews on HEV in high
income countries [9] and case series of acute HEV infection from
France [10] and UK [11] also did not identify it as an etiological
agent of ALF and ACLF. For this reason, we stated that HEV Geno-
type 3 and 4 (documented as the cause of autochthonous HEV
infection) probably cause more benign disease than the Genotype
1 and 2 HEV infections [4]. The information provided by Peron
et al. [1] may therefore indicate that HEV genotype 3 is associated
with the causation of liver failure (i.e. ACLF) in individuals with
pre-existing liver disease (particularly alcoholic liver disease)
and ALF. Although such infection may be infrequent, prospective
studies in ALF, particularly in France and UK, are needed to estab-
lish HEV genotype 3 as an etiological agent of ALF in these geo-
graphical areas.
We also agree with the authors of the letter to editor that the
initial promise of Ribavirin as an antiviral agent against HEV
infection needs prospective evaluation in a well designed study
with a large number of patients with active viremia.
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